Ir para o conteúdo principal

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) — Perfil da empresa, notícias e dados financeiros

Logo de Tonix Pharmaceuticals Holding
TNXP Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals Holding  primary media
Perfil da empresa

Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals (NASDAQ:TNXP) is a research-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to improve the lives of patients suffering from central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases. Dedicated to addressing unmet medical needs, Tonix Pharmaceuticals is actively engaged in developing a diverse portfolio of potential therapeutic solutions. Their projects range from preclinical to phase 3 clinical trials, with objectives to provide groundbreaking treatments for conditions lacking effective medications. The company's mission is to advance healthcare by delivering accessible, effective solutions to those in need, underscoring their commitment to innovation and patient care.

Resumo

Public USParticipação acionária
2007Ano de fundação
103Funcionários
New Jersey, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Tonix Pharmaceuticals Holding

  • TNX-102 SL - A sublingual tablet designed for the management of fibromyalgia and PTSD symptoms.
  • TNX-1800 - A live replicating vaccine being developed for the prevention of COVID-19.
  • TNX-1900 - A potential treatment for chronic migraine prevention, utilizing intranasal administration.
  • TNX-1300 - A biologic designed to treat cocaine intoxication by breaking down cocaine in the blood.

equipe executiva do Tonix Pharmaceuticals Holding

  • Seth LedermanCo-Founder, Interim Chief Medical Officer, President, CEO & Chairman
  • Bradley SaengerCFO & Treasurer
  • Jessica Edgar MorrisChief Operating Officer
  • Gregory M. SullivanSecretary
  • Siobhan FogartyChief Technical Officer
  • Irina IshakGeneral Counsel
  • Darryl RideoutExecutive Vice President of Experimental Chemistry
  • Sina BavariExecutive Vice President of Infectious Disease Research & Development
  • Zeil RosenbergExecutive Vice President of Medical
  • Thomas EngleseChief Commercial Officer

Principais indicadores financeiros

Resultados divulgados pela Tonix Pharmaceuticals Holding , em USD.

Cap. de mercado
92,1 mi
Receita (TTM)
29,1 mi
P/L
—
LPA (diluído, TTM)
-13.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Tonix Pharmaceuticals Holding
Fim do ano fiscalReceitaResultado operacionalLucro líquido
13,1 mi-125,7 mi-124 mi
10,1 mi-136,7 mi-130 mi
7,8 mi-118,4 mi-116,7 mi
9 mi-112,1 mi-115 mi